Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Market: Market:

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Atossa Therapeutics Announces Clinical Progress GlobeNewswire - Thu Apr 2, 7:00AM CDT
CMTX - Thu Apr 2, 7:00AM CDT

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced...

ATOS : 1.5000 (+44.23%)
New Research: While Mid-Size Banks Gain Efficiencies Through Scale, They Come Up Short on Delivery of Digital and Automated Services PR Newswire - Mon Mar 30, 7:37AM CDT
CMTX - Mon Mar 30, 7:37AM CDT

Cornerstone Advisors today released the Cornerstone Performance Report for Banks 2019, the thirteenth in a series of benchmarking studies published by the firm. According to the report's findings, despite...

ATOS : 1.5000 (+44.23%)
New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients GlobeNewswire - Mon Mar 30, 7:00AM CDT
CMTX - Mon Mar 30, 7:00AM CDT

Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update GlobeNewswire - Thu Mar 26, 7:00AM CDT
CMTX - Thu Mar 26, 7:00AM CDT

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics Announces Upcoming Meeting with FDA GlobeNewswire - Fri Mar 13, 7:30AM CDT
CMTX - Fri Mar 13, 7:30AM CDT

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density GlobeNewswire - Mon Mar 2, 7:30AM CST
CMTX - Mon Mar 2, 7:30AM CST

Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference GlobeNewswire - Wed Feb 5, 7:00AM CST
CMTX - Wed Feb 5, 7:00AM CST

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment" ACCESSWIRE - Tue Feb 4, 4:10PM CST
CMTX - Tue Feb 4, 4:10PM CST

Every February 4th is , the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective,...

ATOS : 1.5000 (+44.23%)
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020 GlobeNewswire - Wed Jan 22, 7:30AM CST
CMTX - Wed Jan 22, 7:30AM CST

Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc. GlobeNewswire - Mon Jan 6, 7:00AM CST
CMTX - Mon Jan 6, 7:00AM CST

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women GlobeNewswire - Thu Dec 19, 8:03AM CST
CMTX - Thu Dec 19, 8:03AM CST

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019 GlobeNewswire - Thu Dec 5, 7:30AM CST
CMTX - Thu Dec 5, 7:30AM CST

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update GlobeNewswire - Wed Nov 13, 7:00AM CST
CMTX - Wed Nov 13, 7:00AM CST

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference GlobeNewswire - Wed Oct 23, 7:30AM CDT
CMTX - Wed Oct 23, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology GlobeNewswire - Wed Oct 16, 7:30AM CDT
CMTX - Wed Oct 16, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research...

ATOS : 1.5000 (+44.23%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia ACCESSWIRE - Tue Oct 15, 11:49AM CDT
CMTX - Tue Oct 15, 11:49AM CDT

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.5000 (+44.23%)
JNJ : 139.76 (+4.17%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia ACCESSWIRE - Tue Oct 15, 11:47AM CDT
CMTX - Tue Oct 15, 11:47AM CDT

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.5000 (+44.23%)
JNJ : 139.76 (+4.17%)
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen GlobeNewswire - Mon Sep 30, 7:30AM CDT
CMTX - Mon Sep 30, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary...

ATOS : 1.5000 (+44.23%)
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference GlobeNewswire - Fri Sep 6, 8:56AM CDT
CMTX - Fri Sep 6, 8:56AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.5000 (+44.23%)
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet GlobeNewswire - Tue Sep 3, 7:01AM CDT
CMTX - Tue Sep 3, 7:01AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all...

ATOS : 1.5000 (+44.23%)
Please wait...

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
Mon Dec 30, 3:58PM CST
CRUS +6.62 , SEDG +10.67 , THC +1.63 , TER +6.34 , LITE +7.94
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot